Introduction {#Sec1}
============

Daptomycin is a cyclic lipopeptide antibiotic that is approved at a dose of 4 mg/kg/day for the treatment of complicated skin and soft tissue infections (cSSTI) and at a dose of 6 mg/kg/day for the treatment of *Staphylococcus aureus* right-sided infective endocarditis (RIE) and bacteremia associated with cSSTI and RIE \[[@CR1]\]. It has a rapid, concentration-dependent bactericidal activity \[[@CR2]\]. Daptomycin exhibits a linear pharmacokinetic profile, which is concentration proportional for doses up to 12 mg/kg/day \[[@CR2]--[@CR4]\]. As a result of its concentration-dependent bactericidal activity, higher doses (\>6 mg/kg/day) have often been considered for difficult-to-treat infections \[[@CR5]\].

Daptomycin is a recognized alternative to vancomycin for the treatment of serious infections \[[@CR6]\]. Optimum dosing of daptomycin for serious/deep-seated infection is not yet defined. Based on its concentration-dependent activity, higher doses of daptomycin may lead to a more rapid bacterial clearance and reduce resistance emergence \[[@CR5], [@CR7]\]. In infections where there is a difficulty in achieving adequate local antibiotic concentration at the infection site, or in patients with sepsis and high volumes of distribution, high-dose daptomycin may also be advantageous \[[@CR4], [@CR8]\]. Additionally, the intrinsic lower susceptibility of enterococci to daptomycin suggests that high doses of daptomycin may be necessary to achieve good results \[[@CR9]\].

Several national and international treatment guidelines include high-dose daptomycin (8--10 mg/kg/day) as a therapeutic option for difficult-to-treat infections \[[@CR6], [@CR10]--[@CR12]\]. The Infectious Diseases Society of America guidelines for the treatment of methicillin-resistant *S. aureus* (MRSA) recommend consideration of high-dose (10 mg/kg/day) daptomycin in patients with persistent MRSA bacteremia associated with vancomycin failure and possible endocarditis \[[@CR6]\]. Also, the Spanish Society of Infectious Diseases and Clinical Microbiology has recently addressed the impact of an appropriate antimicrobial treatment (empirical and directed) and its relevance in the management of *S. aureus* infections, and the role of high-dose daptomycin in these scenarios \[[@CR11]\].

Although only a limited number of clinical trials have evaluated the safety of high-dose daptomycin \[[@CR5], [@CR13], [@CR14]\], several observational studies have reported the successful use of high-dose daptomycin (\>6 mg/kg/day) in patients with difficult-to-treat infections \[[@CR7]--[@CR9], [@CR15]--[@CR18]\]. To date, there are no randomized controlled studies that have evaluated the efficacy and safety of high-dose daptomycin. The objective of this analysis from the European Cubicin^®^ Outcomes Registry and Experience (EU-CORE) study was to evaluate the effectiveness and safety of daptomycin for the treatment of Gram-positive infections in a real-world setting with high doses (\>6 mg/kg/day) versus current licensed doses (4 or 6 mg/kg/day).

Methods {#Sec2}
=======

Study Design and Data Collection {#Sec3}
--------------------------------

This was a non-interventional, multicenter, retrospective, patient registry designed to collect real-world outcome data on patients who had received at least one dose of daptomycin for the treatment of a serious Gram-positive bacterial infection. This analysis includes all patients enrolled in the EU-CORE study who received any dose of daptomycin between 2006 and 2012: ≤6 mg/kg/day, \>6 to \<8 mg/kg/day, or ≥8 mg/kg/day.

Detailed EU-CORE methodology has been described elsewhere \[[@CR19]\]. Patients who had received at least one dose of daptomycin, had a minimum of 30 days post-treatment follow-up for safety monitoring, and were not part of a controlled clinical trial, were included. Daptomycin treatment was considered to be first line when there was no prior use of antibiotics and second line if prior antibiotics were used. In this analysis, patients treated with doses \>6 mg/kg/day of daptomycin were compared with doses ≤6 mg/kg/day.

Institutional Review Board (IRB) or Ethics Committee (EC) approval in each country was obtained before the start of the study and all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013, and Good Clinical Practices. Informed consent was obtained according to the requirements of the IRB or EC and/or local data privacy regulations.

Effectiveness {#Sec4}
-------------

Investigators assessed clinical outcomes at the end of daptomycin therapy according to protocol-defined criteria: cured (clinical signs and symptoms resolved, no additional antibiotic therapy was necessary, or infection cleared with a negative culture reported); improved (partial resolution of clinical signs and symptoms and/or additional antibiotic therapy was warranted); failed (inadequate response to daptomycin therapy, worsening or new/recurrent signs and symptoms, need for a change in antibiotic therapy, or positive culture reported at the end of therapy); or non-evaluable (unable to determine response due to insufficient information) \[[@CR20]\]. Clinical success was defined as cured or improved outcomes.

Safety {#Sec5}
------

Adverse events (AEs) and serious AEs (SAEs) during daptomycin treatment and the 30-day follow-up period were assessed by the investigators. All reported AEs were recorded, regardless of their relationship to daptomycin.

Statistical Analysis {#Sec6}
--------------------

Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). Due to the nature of the trial, inferential analyses were not conducted and no formal statistical methodology other than simple descriptive statistics was used. All analyses were considered to be explanatory.

Numerical variables are summarized as arithmetic mean, standard deviation, median, minimum, first quartile, third quartile, and maximum for continuous variables. Categorical variables were summarized by absolute and relative frequencies.

Simple and multiple post-hoc logistic regression analyses were performed to determine whether any factors could have influenced success rates. These factors included the dose level, duration of treatment, bacteremia, comorbidity, use of prior or concomitant medication, and surgery.

Results {#Sec7}
=======

Patient Demographic and Clinical Characteristics {#Sec8}
------------------------------------------------

Of the 6075 patients enrolled in EU-CORE study, 4892 (80.5%) patients received daptomycin doses ≤6 mg/kg/day, 1097 (18.1%) patients received daptomycin doses \>6 mg/kg/day, and dosing information was missing for 86 patients. Baseline demographics, clinical characteristics, and significant underlying diseases are summarized in Table [1](#Tab1){ref-type="table"}. The three dose groups (≤6; \>6 to \<8; ≥8 mg/kg/day) were similar in terms of age, gender, race, and underlying conditions. Of the 5989 patients with reported dosing information, 782 (13.1%) had a baseline creatinine clearance (CrCl) \<30 mL/min. Overall, 542 (9.0%) patients were on dialysis at initiation of daptomycin therapy and 526 (8.8%) patients at end of daptomycin therapy. The proportion of patients with CrCl \<30 mL/min who received daptomycin every 48 h was 44.0%, while 47.0% received daptomycin every 24 h. Among patients undergoing continuous renal replacement therapy (CRRT), 77.2% received daptomycin every 24 h.Table 1Demographic and baseline characteristics (safety population)Characteristic*N* = 5989≤6 mg/kg/day (*N* = 4892), *n* (%)\>6 to \<8 mg/kg/day (*N* = 452), *n* (%)≥8 mg/kg/day (*N* = 645), *n* (%)Gender, male3084 (63.0)270 (59.7)382 (59.2)Age, *N* \<65 years2645 (54.1)250 (55.3)345 (53.5) ≥65 years2242 (45.8)202 (44.7)300 (46.5) ≥75 years1026 (21.0)94 (20.8)150 (23.3) Missing5 (0.1)0 (0.0)0 (0.0)Race, caucasian4238 (86.6)374 (82.7)544 (84.3)Renal function Creatinine clearance \<30 mL/min672 (13.7)47 (10.4)63 (9.8) Patients on dialysis  At initiation of therapy471 (9.6)31 (6.9)40 (6.2)  At end of therapy452 (9.2)31 (6.9)43 (6.7)Significant underlying diseases (\>10%) Cardiovascular2654 (54.3)248 (54.9)375 (58.1) Diabetes mellitus1347 (27.5)108 (23.9)128 (19.8) Renal809 (16.5)66 (14.6)76 (11.8) Oncologic762 (15.6)51 (11.3)101 (15.7) Pulmonary646 (13.2)57 (12.6)90 (14.0) Gastrointestinal602 (12.3)53 (11.7)55 (8.5)Prior antibiotic therapy3185 (65.1)306 (67.7)436 (67.6) Penicillins1231 (25.2)128 (28.3)173 (26.8) Glycopeptides1122 (22.9)137 (30.3)198 (30.7)

The primary infections with the largest proportion of patients treated with a high dose (\>6 mg/kg/day) were osteomyelitis (37.1%), foreign body/prosthetic infection (31.6%; mainly orthopedic, intracardiac and intravascular devices), and endocarditis (27.6%; Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Initial daptomycin dose by type of primary infection. *cSSTI* complicated skin and soft tissue infection, *uSSTI* uncomplicated skin and soft tissue infection. ^a^ Septic arthritis, urinary tract infection/pyelonephritis, necrotizing infections, necrotizing fasciitis, surgical/non-surgical antibiotic prophylaxis, neutropenic fever, metastatic abscess, central nervous system infection, not otherwise specified

A trend towards use of higher doses over time was observed, most notably in the treatment of osteomyelitis and foreign body/prosthetic infection (Fig. [2](#Fig2){ref-type="fig"}). Median duration of daptomycin therapy was 10 (range 1--246), 13 (range 1--300), and 14 (range 1--132) days in the ≤6, \>6 to \<8, and ≥8 mg/kg/day groups, respectively. The duration of daptomycin therapy was longer in patients with osteomyelitis, endocarditis, and foreign body/prosthetic infection.Fig. 2High-dose daptomycin use over time. *cSSTI* complicated skin and soft tissue infection

Previous and Concomitant Antibiotic Therapy {#Sec9}
-------------------------------------------

The majority of patients received other antibiotic therapy before daptomycin in the three dose groups. The most common antibiotics administered prior to daptomycin were penicillins and glycopeptides (Table [1](#Tab1){ref-type="table"}). Treatment failure was the most common reason for discontinuation of prior antibiotic therapy (see Appendix 1 in the supplementary material).

Most inpatients received concomitant antibiotics with daptomycin in the three dose groups; those most commonly used for inpatients included carbapenems, penicillins, and cephalosporins.

Microbiology {#Sec10}
------------

Culture samples were available for 4017 (82.1%), 383 (84.7%) and 577 (89.5%) patients treated with ≤6, \>6 to \<8, and ≥8 mg/kg/day, respectively. Approximately, two-thirds of patients had a positive culture and *S.* *aureus* was the most commonly isolated organism (Table [2](#Tab2){ref-type="table"}). Patients in high-dose groups had higher percentage of positive cultures.Table 2Primary pathogens in patients with positive cultures (safety population)Culture result/primary pathogen*N* = 5989≤6 mg/kg/day (*N* = 4892), *n* (%)\>6 to \<8 mg/kg/day (*N* = 452), *n* (%)≥8 mg/kg/day (*N* = 645), *n* (%)Culture results available4017 (82.1)383 (84.7)577 (89.5) Positive culture3099 (63.3)304 (67.3)455 (70.5) *Staphylococcus aureus*1331 (42.9)129 (42.4)194 (42.6)  MRSA733 (55.1)73 (56.6)93 (47.9)  MSSA495 (37.2)47 (36.4)93 (47.9)  Methicillin susceptibility unknown103 (7.7)9 (7.0)8 (4.1) *Staphylococcus epidermidis*485 (15.7)50 (16.4)101 (22.2) Other coagulase-negative staphylococci387 (12.5)36 (11.8)47 (10.3)*Enterococcus* species *Enterococcus faecalis*182 (5.9)13 (4.3)36 (7.9) *Enterococcus faecium*147 (4.7)16 (5.3)20 (4.4) VRE (*E. faecalis* or *E. faecium*)54 (1.7)2 (0.7)8 (1.8) Other *Enterococcus* spp.42 (1.4)3 (1.0)7 (1.5)Other^a^525 (16.9)57 (18.8)50 (11)*MRSA* methicillin-resistant *S. aureus*, *MSSA* methicillin-susceptible *S. aureus*, *VRE* vancomycin-resistant enterococci^a^Includes *Clostridium perfringens*, *Clostridium* spp., *Corynebacterium* spp., *Streptococcus dysgalactiae*, *Peptostreptococcus* spp., *Staphylococcus* spp. (coagulase not specified), *Streptococcus agalactiae* or group B streptococci, *Streptococcus dysgalactiae*, *Streptococcus dysgalactiae dysgalactiae*, *Streptococcus dysgalactiae equisimilis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes* or group A streptococci, *Streptococcus* spp., viridans streptococci, Gram-negative bacilli, Gram-negative cocci, Gram-positive bacilli, Gram-positive cocci, viruses, fungi/yeast, and invalid/ambiguous pathogen code

Effectiveness {#Sec11}
-------------

The overall clinical success rate (i.e., cured or improved) at the end of daptomycin therapy was 82.0% (899/1097) in the high-dose (\>6 mg/kg/day) group and 80.3% (3928/4890) in the ≤6 mg/kg/day dose group. The clinical success rates were consistent for patients with positive cultures and those with negative cultures or no culture data. At 30 days, the clinical success rate was 91.3% (325/356) in the high-dose (\>6 mg/kg/day) group and 90.3% (633/701) in the ≤6 mg/kg/day dose group. Numerically higher clinical success rates were observed with increasing dose for several infections, including endocarditis and foreign body/prosthetic infection (Table [3](#Tab3){ref-type="table"}). Clinical outcome was also higher in coagulase-negative staphylococcal and enterococcal infections (Fig. [3](#Fig3){ref-type="fig"}). The clinical success rates tended to be greater when daptomycin was used as first-line therapy \[82.1% (≤6 mg/kg), 85.1% (\>6 to \<8 mg/kg), and 87.9% (≥8 mg/kg)\] as compared to second-line therapy \[79.2% (≤6 mg/kg), 77.1% (\>6 to \<8 mg/kg), and 81.9% (≥8 mg/kg)\].Table 3Positive blood culture and clinical success rates by primary infection (efficacy population)Primary infection≤6 mg/kg/day\>6 to \<8 mg/kg/day≥8 mg/kg/dayPositive blood culture, *n/N* (%)Clinical success rate, *n/N* (%)Positive blood culture, *n/N* (%)Clinical success rate, *n/N* (%)Positive blood culture, *n/N* (%)Clinical success rate, *n/N* (%)cSSTI125/1689 (7.4)102/125 (81.6)7/117 (6.0)4/7 (57.1)12/100 (12.0)10/12 (83.3)Bacteremia^a^690/1041 (66.3)531/690 (77.0)53/82 (64.6)38/53 (71.7)89/120 (74.2)68/89 (76.4)Endocarditis252/432 (58.3)203/252 (80.6)33/49 (67.3)28/33 (84.8)81/116 (69.8)76/81 (93.8)Foreign body/prosthetic infection114/403 (28.3)83/114 (72.8)15/60 (25.0)13/15 (86.7)43/126 (34.1)39/43 (90.7)Osteomyelitis17/263 (6.5)13/17 (76.5)10/71 (14.1)6/10 (60.0)16/84 (19.0)11/16 (68.8)*cSSTI* complicated skin and soft tissue infection^a^Results of blood cultures may not have been reported for all patientsFig. 3Clinical success by primary pathogen and dose. *CoNS* coagulase-negative staphylococci, *MRSA* methicillin-resistant *S. aureus*, MSSA methicillin-susceptible *S. aureus*

Results of both simple and multiple logistic regression analyses were consistent. As shown in Fig. [4](#Fig4){ref-type="fig"}, the clinical success rate was greater in patients treated with daptomycin doses ≥8 mg/kg/day as compared to ≤6 mg/kg/day, those who were treated for \>28 days as compared to \<14 days, and patients who underwent surgery as compared to no surgery. All the corresponding odds ratios were larger than 1.Fig. 4Logistic regression analysis of clinical success versus failure or non-evaluable. Data are presented as odds ratio and 95% confidence interval. An odds ratio \>1 favors the former category and an odds ratio \<1 favors the latter category

Safety {#Sec12}
------

AEs, SAEs, and 30-day overall mortality rate and mortality due to infections are presented in Table [4](#Tab4){ref-type="table"}. Musculoskeletal and connective tissue disorders were reported as AEs in 25 (0.4%) patients. A total of 12 cases were considered by the investigator as related to daptomycin and among them 5 were SAEs (Table [4](#Tab4){ref-type="table"}). Rhabdomyolysis and myalgia were the most reported AEs possibly related to daptomycin in the ≤6 mg/kg/day group or with higher doses of daptomycin but they were rare (0.2%). Discontinuation of daptomycin was observed in all patients with AEs of musculoskeletal and connective tissue disorders reported as related to daptomycin.Table 4Safety in patients receiving daptomycin by dose group (safety population)Safety parameter≤6 mg/kg/day (*N* = 4892)^a^, *n* (%)\>6 to \<8 mg/kg/day (*N* = 452)^a^, *n* (%)≥8 mg/kg/day (*N* = 645)^a^, *n* (%)Death^b^329 (6.7)40 (8.8)29 (4.5) 30-day mortality272 (5.6)33 (7.3)26 (4.0) 30-day mortality due to infections138 (2.8)16 (3.5)17 (2.6)Any SAE448 (9.2)62 (13.7)57 (8.8) Patients with CrCl \< 30 mL/min dosed every 24 h, *n*/*N* (%)55/301 (18.3)8/27 (29.6)8/33 (24.2)Any AE650 (13.3)94 (20.8)107 (16.6) Patients with CrCl \< 30 mL/min dosed every 24 h, *n*/*N* (%)64/301 (21.3)9/27 (33.3)8/33 (24.2)Any AE by treatment duration^c^ 1--14 days, *n*/*N* (%)440/3238 (13.6)56/252 (22.2)57/324 (17.6) 15--28 days, *n*/*N* (%)136/1072 (12.7)23/112 (20.5)31/173 (17.9) \>28 days, *n*/*N* (%)72/515 (14.0)15/82 (18.3)19/140 (13.6)SAEs possibly related to daptomycin29 (0.6)9 (2.0)10 (1.6)AEs possibly related to daptomycin126 (2.6)24 (5.3)42 (6.5)Patients with AE leading to study drug discontinuation195 (4.0)23 (5.1)30 (4.7)AE of blood creatine phosphokinase increased49 (1.0)9 (2.0)18 (2.8)Musculoskeletal and connective tissue disorders (AEs related to daptomycin)8 (0.2)2 (0.4)2 (0.3) Rhabdomyolysis4 (0.1)^d^0 (0.0)1 (0.2)^d^ Myositis0 (0.0)1 (0.2)^d^0 (0.0) Myalgia3 (0.1)0 (0.0)1 (0.2) Myopathy0 (0.0)1 (0.2)0 (0.0) Muscular weakness1 (0.0)0 (0.0)0 (0.0)*AE* adverse event, *CrCl* creatinine clearance, *SAE* serious AE^a^Unless otherwise indicated^b^Excluding follow-up period^c^Treatment duration may not have been reported for all patients^d^All considered as SAE except one case in the ≤6 mg/kg/day group

Rates of AEs leading to daptomycin discontinuation were similar between dose groups (4.0, 5.1, and 4.7% in the ≤6, \>6 to \<8, and ≥8 mg/kg/day groups, respectively). There were no new or unexpected safety findings at doses \>6 mg/kg/day and no episodes of eosinophilic pneumonia were reported.

Increased blood creatine phosphokinase (CPK) was reported as an AE in 49 (1.0%), 9 (2.0%), and 18 (2.8%) patients in the ≤6, \>6 to \<8, and ≥8 mg/kg/day groups, respectively (Table [4](#Tab4){ref-type="table"}). Shift to worsening CrCl from initiation to end of daptomycin therapy by daptomycin dose was 10.4% or less for all dose ranges \[≤6 mg/kg/day (8.2%), \>6 and \<8 mg/kg/day (10.4%), ≥8 mg/kg/day (9.5%)\].

A total of 782 (13.1%) patients had a baseline CrCl \<30 mL/min. Overall AEs or SAEs were reported at greater frequencies in patients with CrCl \<30 mL/min who received daptomycin every 24 h as compared with the total patient population (Table [4](#Tab4){ref-type="table"}). There were no safety signals associated with daptomycin therapy in these patients.

Discussion {#Sec13}
==========

High-dose daptomycin treatment has been recommended for difficult-to-treat Gram-positive infections within various national and international guidelines \[[@CR6], [@CR10]--[@CR12]\]. Although higher doses of daptomycin are increasingly prescribed for severe infections \[[@CR21]\], there are a few studies evaluating the effectiveness of high dose. Patients within EU-CORE were more likely to be treated with high-dose daptomycin, if they had bacteremia, endocarditis, osteomyelitis, or foreign body/prosthetic infection. Numerically higher clinical success rate was observed with increasing dose in endocarditis and foreign body/prosthetic infection. As previously observed, success rates were higher when daptomycin was used as first-line treatment and this difference was observed across all dosing groups \[[@CR22]\]. Logistic regression analyses revealed that factors contributing to statistically significant higher success rates were dose level (≥8 mg/kg/day), treatment duration (\>28 days), and surgery. The higher success rate in patients treated for \>28 days could be explained by the management of serious infections (e.g., osteomyelitis, endocarditis, and foreign body/prosthetic infection) that typically require a prolonged course of antibiotic therapy.

Effectiveness and safety of high-dose daptomycin treatment has been observed in several difficult-to-treat infections including mediastinitis after cardiac surgery and osteomyelitis \[[@CR23], [@CR24]\]. A retrospective evaluation of the effectiveness and safety of high-dose daptomycin therapy (\>6 mg/kg/day) in a multicenter cohort of 245 adult patients with enterococcal infections showed that high-dose daptomycin was effective and safe \[[@CR9]\]. Furthermore, high-dose daptomycin was shown to be an effective and safe alternative to standard-of-care in the treatment of left-sided endocarditis due to common Gram-positive pathogens \[[@CR15], [@CR16]\]. The clinical success rates observed in the present study for endocarditis are consistent with results from these prior studies where numerically higher clinical success rates were observed with daptomycin doses of at least 8 mg/kg/day.

Daptomycin exhibits concentration-dependent activity \[[@CR3]\] and higher doses of daptomycin are associated with increased degree and speed of bactericidal activity \[[@CR25]\]. Furthermore, since *Enterococcus* species usually have higher minimum inhibitory concentrations (MICs) of daptomycin than other Gram-positive pathogens, patients with enterococcal infections may require higher doses of daptomycin. Increasing prevalence and recognition of reduced susceptibility to glycopeptides amongst staphylococcal species is another reason why high-dose daptomycin can be a therapeutic option of interest. Others have argued that in view of the variability in pharmacokinetic parameters, MIC distribution and pharmacodynamics of important bacterial populations, high-dose daptomycin (10 mg/kg/day) could enhance clinical outcomes in complex infections \[[@CR26]\]. In a retrospective cohort case--control analysis, clinical outcomes of patients treated with either daptomycin (8--10 mg/kg/day) or vancomycin for MRSA bacteremia with vancomycin MIC values ≥1.5 mg/L were compared \[[@CR17]\]. The daptomycin group had a favorable outcome at 14 and 30 days. In agreement with this study, our results confirm that daptomycin doses \>6 mg/kg/day with a median duration of approximately 14 days was effective in the treatment of patients with infections including endocarditis, bacteremia, skin and soft tissue infection, foreign body/prosthetic infection, and osteomyelitis. In patients with renal impairment (CrCl \< 30 mL/min), the recommended dosing interval for daptomycin is every 48 h. Unlike in patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis, the pharmacokinetics of daptomycin in patients receiving CRRT are similar to healthy volunteers. Therefore, dosing frequency in these patients should be every 24 h \[[@CR27], [@CR28]\], as reported in this registry where daptomycin was given every 24 h in 77.8% of patients on CRRT.

This study showed that daptomycin at doses \>6 mg/kg/day was well tolerated with no new or unexpected safety findings. CPK elevation is a well-known safety signal for daptomycin, and baseline and weekly CPK measurement is recommended during high-dose daptomycin therapy. A few studies have reported CPK elevations that led to drug discontinuation due to musculoskeletal symptoms or related AEs \[[@CR13], [@CR14], [@CR25]\], while others have reported high-dose daptomycin to be safe with no elevations of CPK \[[@CR29], [@CR30]\]. Fowler et al. \[[@CR31]\] observed CPK elevations of 6.7% for daptomycin (6 mg/kg every 24 h) versus 0.9% for the comparator group in the complex *S. aureus* bacteremia and endocarditis study. In contrast, CPK elevations observed in the current study in patients treated with high-dose daptomycin were lower (2.0% and 3.0% in the \>6 to \<8 and ≥8 mg/kg/day groups, respectively). Muscular events were rare and seemed to be similar in the three dose groups.

The limitations of this study include the inherent limitations that are expected in real-world observational studies, which include non-randomized trial design, non-blinded interpretation of results, and the subjective assessments of clinical outcomes as determined by individual investigators.

Conclusion {#Sec14}
==========

High-dose daptomycin (\>6 mg/kg/day) exhibited good safety and tolerability profile. These findings, combined with high success rates in a large spectrum of infections and against a wide range of pathogens, suggest that high-dose daptomycin (\>6 mg/kg/day) is a therapeutic option in patients with difficult-to-treat infections and may provide better outcome for some infections.
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